Dose Finding Study of Bucumolol in Angina Pectoris and Arrhythmias:Multiclinical Controlled Double Blind Study

概要

論文の詳細を見る
In order to find out an appropriate therapeutic dose of bucumolol, a newly developped β-blocker, the effects of 30mg/day and 60mg/day of the drug on angina pectoris and arrhythmias were studied by means of double blind group comparison method.<BR>Of 66 patients with angina, general improvement rating was better in 28cases of 30mg/day group than in 38cases of 60mg/day group (P=0.085), while no signifi-cant difference in usefulness was observed between two groups.The rates of decrease of the anginal attacks and nitroglycerin consumption were higher in the former group (P=0.053 and P=0.024).<BR>Of 46 patients with premature beats, general improvement rating and usefulness were significantly better in 24 cases of 30 mg/day group (P=0.025 and P=0.027), but no significant difference was seen in the rate of decrease of premature beats between two groups.<BR>The incidence of side effects was 18 among 132 cases (13.6%).<BR>These data indicate that 30 mg/day of bucumolol is recommended for the treatment of angina and arrhythmias.
一般社団法人日本臨床薬理学会の論文